Cargando…

COVID-19 mRNA Vaccine in Patients With Lymphoid Malignancy or Anti-CD20 Antibody Therapy: A Systematic Review and Meta-Analysis

BACKGROUND: The humoral response to vaccination in individuals with lymphoid malignancies or those undergoing anti-CD20 antibody therapy is impaired, but details of the response to mRNA vaccines to protect against COVID-19 remain unclear. This systematic review and meta-analysis aimed to characteriz...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ito, Yusuke, Honda, Akira, Kurokawa, Mineo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Inc. 2022
Materias:	Original Studies
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8958822/ https://www.ncbi.nlm.nih.gov/pubmed/35459624 http://dx.doi.org/10.1016/j.clml.2022.03.012

Ejemplares similares

Impact of vitamin D level at diagnosis and transplantation on the prognosis of hematological malignancy: a meta-analysis
por: Ito, Yusuke, et al.
Publicado: (2022)

Activity of mRNA COVID-19 vaccines in patients with lymphoid malignancies
por: Crombie, Jennifer L., et al.
Publicado: (2021)

CCDC88C‐FLT3 gene fusion in CD34‐positive haematopoietic stem and multilineage cells in myeloid/lymphoid neoplasm with eosinophilia
por: Kurihara, Yuya, et al.
Publicado: (2022)

586. Immunogenicity of COVID-19 mRNA Vaccines in Patients with Lymphoid Malignancies
por: Izaguirre, Natalie E, et al.
Publicado: (2021)

Immunogenicity of Sars-Cov-2 mRNA 1273 Vaccine in Patients with Lymphoid Malignancies
por: Dong, Ning, et al.
Publicado: (2021)

Prior cycles of anti-CD20 antibodies affect antibody responses after repeated SARS-CoV-2 mRNA vaccination
por: Asashima, Hiromitsu, et al.
Publicado: (2023)

It is time to adapt anti-CD20 administration schedules to allow efficient anti-SARS-CoV-2 vaccination in patients with lymphoid malignancies
por: Besson, Caroline
Publicado: (2021)

Expanding anti-CD38 immunotherapy for lymphoid malignancies
por: Wang, Xu, et al.
Publicado: (2022)

Anti-SARS-CoV-2 antibody response after 2 and 3 doses of BNT162b2 mRNA vaccine in patients with lymphoid malignancies
por: Gressens, Simon B., et al.
Publicado: (2022)

Comparison of mRNA Vaccinations with BNT162b2 or mRNA-1273 in Anti-CD20-Treated Multiple Sclerosis Patients
por: Hammer, Helly, et al.
Publicado: (2022)

Limited increase in antibody titers following mRNA SARS-CoV-2 vaccination for more than 3 years after final dose of anti-CD20 antibody
por: Funakoshi, Yohei, et al.
Publicado: (2022)

Promising Efficacy of a Third Dose of mRNA SARS-CoV-2 Vaccination in Patients Treated with Anti-CD20 Antibody Who Failed 2-Dose Vaccination
por: Funakoshi, Yohei, et al.
Publicado: (2022)

CD62L expression level determines the cell fate of myeloid progenitors
por: Ito, Yusuke, et al.
Publicado: (2021)

Immunogenicity of a Three-Dose Primary Series of mRNA COVID-19 Vaccines in Patients With Lymphoid Malignancies
por: Sherman, Amy C, et al.
Publicado: (2022)

A case of anti-MOG antibody-positive ADEM following COVID-19 mRNA vaccination
por: Miyamoto, Katsuichi, et al.
Publicado: (2022)

Anti-spike T-cell and Antibody Responses to SARS-CoV-2 mRNA Vaccines in Patients with Hematologic Malignancies
por: Greenberger, Lee M., et al.
Publicado: (2022)

Analysis of innate and acquired resistance to anti-CD20 antibodies in malignant and nonmalignant B cells
por: Small, George W., et al.
Publicado: (2013)

Stromal cell inhibition of anti-CD20 antibody mediated killing of B-cell malignancies
por: Fagnano, Ester, et al.
Publicado: (2023)

COVID‑19 antibody production by vaccination in chemotherapy with CD20 antibody for B‑cell lymphoma
por: Tsutsumi, Yutaka, et al.
Publicado: (2023)

Anti-SARS-CoV-2 cellular response after 2 and 3 doses of BNT162b2 mRNA vaccine in lymphoma patients receiving anti-CD20 antibodies
por: Gressens, Simon B., et al.
Publicado: (2023)

Serological and cellular response to mRNA-SARS-CoV2 vaccine in patients with hematological lymphoid malignancies: Results of the study “Cervax”
por: Mohamed, Sara, et al.
Publicado: (2023)

Antibody response in elderly vaccinated four times with an mRNA anti-COVID-19 vaccine
por: Rouvinski, Alexander, et al.
Publicado: (2023)

An Agonistic Anti-CD137 Antibody Disrupts Lymphoid Follicle Structure and T-Cell-Dependent Antibody Responses
por: Hong, Jun P., et al.
Publicado: (2020)

Myocarditis following COVID-19 mRNA vaccination
por: Parmar, Kanak, et al.
Publicado: (2021)

Humoral immune response following SARS-CoV-2 mRNA vaccination concomitant to anti-CD20 therapy in multiple sclerosis()
por: Novak, Frederik, et al.
Publicado: (2021)

Antibody Response to Vaccination with BNT162b2, mRNA-1273, and ChADOx1 in Patients with Myeloid and Lymphoid Neoplasms
por: Rotterdam, Jil, et al.
Publicado: (2021)

Generation of CD20-specific TCRs for TCR gene therapy of CD20(low) B-cell malignancies insusceptible to CD20-targeting antibodies
por: Jahn, Lorenz, et al.
Publicado: (2016)

Phase I study of Nivolumab, an anti-PD-1 antibody, in patients with malignant solid tumors
por: Yamamoto, Noboru, et al.
Publicado: (2016)

Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy
por: Apostolidis, Sokratis A., et al.
Publicado: (2021)

Myocarditis rare after COVID-19 mRNA vaccination
Publicado: (2021)

Safety of mRNA COVID-19 vaccines during pregnancy
Publicado: (2022)

Surface Levels of CD20 Determine Anti-CD20 Antibodies Mediated Cell Death In Vitro
por: Singh, Vijay, et al.
Publicado: (2014)

Modulation of deoxycytidine kinase (dCK) and glycogen synthase kinase (GSK-3β) by anti-CD20 (rituximab) and 2-chlorodeoxyadenosine (2-CdA) in human lymphoid malignancies
por: Al-Katib, Ayad M, et al.
Publicado: (2014)

Sars-CoV2 Antibody Responses in Patients with Hematological Malignancies Following Anti-CD20 Therapy
por: Guerra, Veronica A, et al.
Publicado: (2021)

Novel chimerized IgA CD20 antibodies: Improving neutrophil activation against CD20-positive malignancies
por: Evers, Mitchell, et al.
Publicado: (2020)

Characterization of anti-CD20 monoclonal antibody produced by transgenic silkworms (Bombyx mori)
por: Tada, Minoru, et al.
Publicado: (2015)

T‐cell immune response after mRNA SARS‐CoV‐2 vaccines is frequently detected also in the absence of seroconversion in patients with lymphoid malignancies
por: Marasco, Vincenzo, et al.
Publicado: (2021)

Anti-CD20 Depletes Meningeal B Cells but Does Not Halt the Formation of Meningeal Ectopic Lymphoid Tissue
por: Brand, Rosa Margareta, et al.
Publicado: (2021)

Ofatumumab: a novel monoclonal anti-CD20 antibody
por: Lin, Thomas S
Publicado: (2010)

Anti-CD20 monoclonal antibodies: reviewing a revolution
por: Casan, J. M. L., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ujde9v5iqtkvaialg7boraalto